1. 308 Tralokinumab provides other clinically meaningful improvements in adolescents with moderate-to-severe atopic dermatitis who did not achieve IGA 0/1 at week 16. (25th January 2023) Authors: Paller, Amy; Blauvelt, Andrew; Soong, Weily; Hong, Chih-ho; Schuttelaar, Marie L A; Schneider, Shannon ; Moerch, Marie Holst; Simpson, Eric Journal: British journal of dermatology Issue: Volume 188(2023)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 314 Injection site reactions from an integrated analysis of phase 2 and phase 3 clinical trials of lebrikizumab treatment in moderate-to-severe atopic dermatitis. (25th January 2023) Authors: Gooderham, Melinda; Shi, Vivian Y; Wollenberg, Andreas; Thyssen, Jacob P; Torres, Tiago; Gil, Esther Garcia; Bardolet, Laia; Natalie, Chitra R; Atwater, Amber R; Zhao, Fangyi; Blauvelt, Andrew Journal: British journal of dermatology Issue: Volume 188(2023)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 322 Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2). (25th January 2023) Authors: Blauvelt, Andrew; Thyssen, Jacob P; Guttman-Yassky, Emma ; Bieber, Thomas; Carrascosa, Jose Manuel; Simpson, Eric; Rosmarin, David ; Elmaraghy, Hany; Meskimen, Eric; Natalie, Chitra R; Liu, Zhuqing; Xu, Chenjia; Pierce, Evangeline; Morgan-Cox, MaryAnn; Silverberg, Jonathan I Journal: British journal of dermatology Issue: Volume 188(2023)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 355 Efficacy of upadacitinib for moderate-to-severe atopic dermatitis: analysis of time spent in skin clearance response states from the Measure Up 1, Measure Up 2 and Heads Up studies. (25th January 2023) Authors: Blauvelt, Andrew; Silverberg, Jonathan I; Calimlim, Brian M ; Liu, Yingyi; Platt, Andrew; Thyssen, Jacob P Journal: British journal of dermatology Issue: Volume 188(2023)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial. (1st June 2020) Authors: Blauvelt, A.; Papp, K.; Gottlieb, A.; Jarell, A.; Reich, K.; Maari, C.; Gordon, K.B.; Ferris, L.K.; Langley, R.G.; Tada, Y.; Lima, R.G.; Elmaraghy, H.; Gallo, G.; Renda, L.; Park, S.Y.; Burge, R.; Bagel, J.; Vender, Ronald; Lomaga, Mark A.; Delorme, Isabelle Journal: British journal of dermatology Issue: Volume 182:Number 6(2020) Page Start: 1348 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study to evaluate the efficacy and safety of VT‐1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail. (1st February 2021) Authors: Elewski, B.; Brand, S.; Degenhardt, T.; Curelop, S.; Pollak, R.; Schotzinger, R.; Tavakkol, A.; Alonso‐Llamazares, Javier; Ashton, Scott J.; Bhatia, Neal; Billings, Michael; Blauvelt, Andrew; Bystol, Norman; Dodson, Brandt; Gold, Michael H.; Grande, Kimberly; Jarratt, Michael; Jones, Terry S.; Ka... Journal: British journal of dermatology Issue: Volume 184:Number 2(2021) Page Start: 270 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. AB0738 DUAL NEUTRALISATION OF INTERLEUKIN (IL)–17A AND IL–17F WITH BIMEKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 60-WEEK RESULTS FROM A RANDOMISED, DOUBLE-BLINDED, PHASE 2B EXTENSION STUDY. (June 2019) Authors: Blauvelt, Andrew; Papp, Kim a.; Merola, Joseph F.; Gottlieb, Alice B.; Cross, Nancy; Madden, Cynthia; Wang, Maggie; Cioffi, Christopher; Griffiths, Christopher E.M. Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 1834 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life. (4th July 2022) Authors: Blauvelt, Andrew; Boguniewicz, Mark; Brunner, Patrick M.; Luna, Paula C.; Biswas, Pinaki; DiBonaventura, Marco; Farooqui, Saleem A.; Rojo, Ricardo; Cameron, Michael C. Journal: Journal of dermatological treatment Issue: Volume 33:Number 5(2022) Page Start: 2605 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index. Issue 8 (1st July 2021) Authors: Bykerk, Vivian P.; Blauvelt, Andrew; Curtis, Jeffrey R.; Gaujoux‐Viala, Cécile; Kvien, Tore K.; Winthrop, Kevin; Tilt, Nicola; Popova, Christina; Mariette, Xavier; Haraoui, Boulos Journal: ACR open rheumatology Issue: Volume 3:Issue 8(2021) Page Start: 501 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Issue 10273 (6th February 2021) Authors: Gordon, Kenneth B; Foley, Peter; Krueger, James G; Pinter, Andreas; Reich, Kristian; Vender, Ronald; Vanvoorden, Veerle; Madden, Cynthia; White, Katy; Cioffi, Christopher; Blauvelt, Andrew Journal: Lancet Issue: Volume 397:Issue 10273(2021) Page Start: 475 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗